LoQus23 Therapeutics
Biotechnology Research • 
Cambridge, England, United Kingdom • 11-20 Employees
Company overview
| Headquarters | Building 522, Riverside, Ivan de Burgh Room, Cambridge, Cambridgeshire CB22 3AT, GB |
| Website | |
| NAICS | 541714 |
| Employees | 11-20 |
| Socials |
Key Contact at LoQus23 Therapeutics
Deborah Tonge
Financial Director
LoQus23 Therapeutics Email Formats
LoQus23 Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@loqus23.com), used 90.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@loqus23.com | 90.9% |
{first name}{last name} | johndoe@loqus23.com | 9.1% |
About LoQus23 Therapeutics
LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat expansion diseases. Huntington’s disease is an autosomal dominant neurodegenerative disorder for which there is currently no disease modifying treatment available and which currently has 30,000 patients in the US alone. LoQus23’s approach has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases. LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other advanced treatment modalities. LoQus23’s lead programme, a potent allosteric small molecule MSH3 inhibitor, part of the MutSβ complex, will enter the clinic in 2026. LoQus23 has a highly experienced leadership team, built on world-class science. It was originally established in 2019 by Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan CBE, FMedSci, Entrepreneurs in Residence at SV Health Investors’ Dementia Discovery Fund, which also acted as the initial seed investor. In October 2024, the Company closed a successful £35 million Series A financing round led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund and Novartis Venture Fund.
LoQus23 Therapeutics revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $67,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,200,000 |
| Total funding | $55,800,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
LoQus23 Therapeutics has 4 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore LoQus23 Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
LoQus23 Therapeutics Tech Stack
Discover the technologies and tools that power LoQus23 Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Video players
Font scripts
JavaScript libraries
Hosting
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Maps
Databases
Miscellaneous
Performance
United States
France
Australia
Frequently asked questions
4.8
40,000 users
